Progression of Hematopoietic Diseases in Shanghai, China

Hematologic Diseases Clinical Trial

Official title:

Analysis of Disease Progression for Aplastic Anemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia and Benzene Poisoning in Shanghai, China.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00365014
• Other study ID #: 02-0036
• Status: Completed
• Phase: N/A
• First received: August 14, 2006
• Last updated: July 19, 2013
• Start date: August 2003
• Est. completion date: December 2009

Study information

• Verified date: July 2013
• Source: University of Colorado, Denver
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review BoardChina: Ministry of Health
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to identify and characterize blood diseases presenting at Shanghai hospitals and to compare them with respect to clinical presentation, phenotype, molecular characteristics, benzene or other exposures and genetic susceptibility.

Description:

The purpose of this study is to identify and characterize blood diseases presenting at Shanghai hospitals and to compare them with respect to clinical presentation, phenotype, molecular characteristics, benzene or other exposures and genetic susceptibility. The format for these studies is a set of clinical series superimposed on a case-control design that enables integration of detailed clinical and molecular characterizations of disease pathogenesis together with an evaluation of potential confounding and interacting factors within a structured statistical analysis of benzene exposure.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10757
• Est. completion date: December 2009
• Est. primary completion date: December 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Men and women 18 years or older Diagnosis of hematologic abnormality

Exclusion Criteria:

Children Non hematologic diseases

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Hematologic Diseases
• Myelodysplastic Syndromes
• Preleukemia

Locations

Country	Name	City	State
China	Joint Sino-US Clinical and Molecular Laboratory (JCML)	Shanghai

Sponsors (10)

Lead Sponsor	Collaborator
University of Colorado, Denver	British Petroleum P.L.C., Chevron Corporation, ConocoPhillips, Exxon Mobil, ExxonMobil Biomedical Sciences, Inc., Fudan University, Marathon Ashland, Shell Chemicals, University of Cincinnati

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	blood diseases presenting at Shanghai hospitals	characterization of people with blood diseases presenting at Shanghai hospitals	hospital stay	No